ReviewCurrent gastroenterology reports2025
Diagnosis and Management of Food Protein-Induced Allergic Proctocolitis.
Review in Current gastroenterology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewFood protein-induced allergic proctocolitis (FPIAP) is a frequent cause of rectal bleeding in otherwise healthy infants. Although benign and self-limited, wide variation in diagnostic and management practices often leads to overdiagnosis, unnecessary dietary restriction, and disruption of breastfeeding. This review summarizes contemporary evidence to guide a pragmatic, challenge-anchored approach to diagnosis and management. RECENT
findingsDiagnosis of FPIAP remains clinical, based on symptom resolution after elimination and recurrence upon reintroduction of the trigger food; however, confirmatory challenges are seldom performed. Fecal calprotectin and other proposed biomarkers-such as eosinophil-derived neurotoxin, zonulin, and microbiome signatures-show poor reliability in infants and are not ready for clinical use. Management should prioritize the least restrictive diet - maternal dairy elimination for breastfed infants and extensively hydrolyzed formulas for formula-fed infants - only in challenge-proven FPIAP. Growing data support earlier reintroduction once colitis resolves, and early introduction of other allergens may reduce future IgE-mediated allergy risk. A standardized, challenge-confirmed framework minimizes over-restriction and supports continued breastfeeding. Future priorities include validation of non-invasive biomarkers and trials comparing timing and strategies for safe dietary reintroduction in FPIAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.